



# Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA)

## SCIENTIFIC COMMITTEE MEMBERS AND EXPERTS

### I, **Alessia Pochesci**

Organisation/Company: N/A

Country: Luxembourg

Declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical companies and in medical device companies are those listed below:

#### Pharmaceutical company interests

##### 1.1 Employment

No interest declared

##### 1.2 Consultancy

No interest declared

##### 1.3 Strategic advisory role

No interest declared

##### 1.4 Financial interests

No interest declared

##### 1.5 Principal investigator

No interest declared

##### 1.6 Investigator

Time Period	Start Date	End Date	Name of pharmaceutical company	Product Name	Therapeutic indication
Past	01-02-2015	31-12-2017	Taiho Oncology	TAS-114 + S-1	lung cancer
Past	01-06-2011	31-01-2015	Novartis	Everolimus	advanced/metastatic breast cancer
Past	01-02-2015	31-12-2017	MSD	Pembrolizumab	lung cancer
Past	01-02-2015	31-12-2017	AstraZeneca	Osimertinib	lung cancer
Past	01-02-2015	31-12-2017	BMS	Nivolumab+Ipilimumab	lung cancer
Past	01-02-2015	31-12-2017	Novartis	Ceritinib	lung cancer

Past	01-02-2015	31-12-2017	Xcovery Holding Company	Ensartinib	lung cancer
Past	01-02-2015	31-12-2017	Mirati	Glesatinib	lung cancer
Past	01-02-2015	31-12-2017	Celgene	Nab-paclitaxel	lung cancer
Past	01-02-2015	31-12-2017	Novartis	Capmatinib	lung cancer
Past	01-02-2015	31-12-2017	ARIAD Pharmaceuticals	Brigatinib	lung cancer
Past	01-02-2015	31-12-2017	Merck KGaA	MSC2156119J	lung cancer
Past	01-02-2015	31-12-2017	Roche	Atezolizumab	lung cancer
Past	01-02-2015	31-12-2017	Merck KGaA	Avelumab	lung cancer
Past	01-02-2015	31-12-2017	AstraZeneca	Durvalumab+Tremelimumab	lung cancer
Past	01-02-2015	31-12-2017	Roche	Alectinib	lung cancer
Past	01-02-2015	31-12-2017	Merck KGaA	Tepotinib	lung cancer
Past	01-02-2015	31-12-2017	Boehringer Ingelheim	Afatinib	lung cancer
Past	01-02-2015	31-12-2017	Pierre-Fabre	Vinorelbine	lung cancer

## 1.7 Grant / Funding to organisation /institution

No interest declared

## 1.8 Close family member interest

No interest declared

## 1.9 Repurposing of a medicinal product

No interest declared

## 1.10 Any other interests or facts

In the past (between 2011 and 2017), sub-investigator of clinical trial developed and sponsored by academic institutions. Between Jan 2018 and Feb 2021, employee of an academic sponsor of clinical trial in oncology (European Organization for Research and Treatment of Cancer - EORTC)

## 1.11 Committee for Advanced Therapies (CAT) member or alternate

### 1.11.1 Employment

No interest declared

### 1.11.2 Consultancy

No interest declared

### 1.11.3 Strategic advisory role

No interest declared

### 1.11.4 Financial interest

No interest declared

### 1.11.5 Clinical investigator

Time Period	Start Date	End Date	Name of company	Product name	Indication/use
-------------	------------	----------	-----------------	--------------	----------------

Current	12-04-2023		Viewmind	VR Headset (medical device)	COVID-19
---------	------------	--	----------	-----------------------------	----------

### 1.11.6 Grant / Funding to organisation/institution

No interest declared

### 1.11.7 Close family member interest

No interest declared

### 1.11.8 Any other interests or facts

as Employee of Luxembourg Institut of Health (public research organisation in Luxembourg), I am involved as medical principal investigator in biomedical studies (samples/data collection) and medical device studies (currently only the one declared in the field: 2.1.11.5 CLINICAL INVESTIGATOR)

## Medical device company interests

### 2.1 Employment

No interest declared

### 2.2 Consultancy

No interest declared

### 2.3 Strategic advisory role

No interest declared

### 2.4 Financial interests

No interest declared

### 2.5 Principal investigator

Time Period	Start Date	End Date	Name of medical device company	Product Name	Medical indication/intended purpose
Current	12-04-2023		Viewmind	VR Headset (medical device)	COVID-19

### 2.6 Investigator

No interest declared

### 2.7 Grant / Funding to organisation /institution

No interest declared

### 2.8 Close family member interest

No interest declared

### 2.9 Any other interests or facts

No interest declared

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party <sup>1</sup> any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to indicate clearly that the views are my own if acting in my own capacity or those of the EMA, Management Board, Committee, Working Party, Expert Group or other group if acting on behalf of that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate and complete to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

*1. Third party does not include employees of the National Competent Authorities who either have employment contracts that provide confidentiality obligations or are encompassed by confidentiality obligations under national legislation on professional secrecy.*

Full Name: Alessia Pochesci

Date: 2024-02-07

For definitions of activities etc, refer to the policy on handling of competing interests.